Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is “Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)”. This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional … Continue reading Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

U.S. health regulators on Friday approved a Celgene Corporation (NASDAQ:CELG) drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling. Celgene Corporation (NASDAQ:CELG) stock performance was -3.74% in last session and finished the day at $144.40. Traded volume was 9.50million shares in the last session and the average volume of the stock remained … Continue reading Biotech Active Stocks: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals (NASDAQ:ARNA), Cell Therapeutics (NASDAQ:CTIC), Inovio Pharmaceuticals (NYSEMKT:INO)

Mast Therapeutics Inc (NYSEMKT:MSTX) announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires’ lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension. Mast Therapeutics Inc (NYSEMKT:MSTX) stock performance was 12.12% in last session and finished the day at $0.828. Traded volume was … Continue reading Biotech Active Stocks: Mast Therapeutics Inc (NYSEMKT:MSTX), Geron Corporation (NASDAQ:GERN), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Arena Pharmaceuticals Inc (NASDAQ: ARNA ) and VIVUS (NASDAQ: VVUS ) in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -2.84% in last session and finished the day at $6.49. Traded volume was 6.83million shares in the last session and the average … Continue reading Active Stocks Healthcare: Arena Pharmaceuticals (NASDAQ:ARNA), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), Teva Pharmaceutical Industries (NYSE:TEVA)

CytRx Corporation (NASDAQ:CYTR) reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -12.76% in last session and finished the day at $4.17. Traded volume was 11,065,087 million shares in the last session and the average volume of the stock remained 3.51 … Continue reading Biotech Losers: CytRx Corporation (NASDAQ:CYTR), Galena Biopharma (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume … Continue reading Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)